Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EPS (Basic) (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed EPS (Basic) for 12 consecutive years, with -$2.19 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) fell 323.47% year-over-year to -$2.19, compared with a TTM value of $122.64 through Sep 2025, up 763.64%, and an annual FY2024 reading of -$7.94, up 93.01% over the prior year.
  • EPS (Basic) was -$2.19 for Q3 2025 at Avalo Therapeutics, down from -$1.93 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $128.01 in Q4 2024 and bottomed at -$1059.6 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$61.46, with a median of -$0.88 recorded in 2021.
  • The sharpest move saw EPS (Basic) crashed 27480.1% in 2022, then skyrocketed 990.91% in 2024.
  • Year by year, EPS (Basic) stood at $3.87 in 2021, then tumbled by 27480.1% to -$1059.6 in 2022, then surged by 111.09% to $117.47 in 2023, then rose by 8.97% to $128.01 in 2024, then plummeted by 101.71% to -$2.19 in 2025.
  • Business Quant data shows EPS (Basic) for AVTX at -$2.19 in Q3 2025, -$1.93 in Q2 2025, and -$1.25 in Q1 2025.